Immatics N.V. (IMTX) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Taysha Gene Therapies (TSHA) has outperformed Immatics N.V. (IMTX) over the past year, losing 6.1% versus a loss of 20.8%. Over five years, IMTX leads with a -46.2% price change compared with -75.2% for TSHA. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.13 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | TSHA |
|---|---|---|
| Share price | $7.45 | $4.43 |
| Market cap | $1.13B | $1.44B |
| 1-day change | -0.67% | +0.91% |
| YTD return | -29.05% | -19.45% |
| 1-year return | -20.83% | -6.14% |
| 5-year return | -46.21% | -75.22% |
| EPS (TTM) | $-1.87 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.41 | $7.30 |
| 52-week low | $7.31 | $3.69 |
| Distance from 52-week high | -39.97% | -39.32% |
| Analyst consensus | none | none |
| Avg. price target upside | +136.64% | +193.45% |
| Average volume | 589.82K | 3.25M |
| Shares outstanding | 152.23M | 325.83M |
| Employees | 704 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TSHA has outperformed IMTX by 14.7 percentage points over the past year.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
IMTX vs TSHA FAQ
Which is bigger, Immatics N.V. or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.13B for Immatics N.V. (IMTX).
Which stock has performed better over the past year, IMTX or TSHA?
TSHA returned -6.14% over the past 12 months, compared with -20.83% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.